Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
NCT05197881 · View on ClinicalTrials.gov ↗
Study Summary
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Conditions Studied
Interventions
- DEVICE Varian Ethos Adaptive Radiation Therapy
Study Locations (5)
Alabama
- University of Alabama Birmingham — Burmingham
Arkansas
- University of Arkansas Medical Sciences — Little Rock
California
- Moores Cancer Center at UC San Diego Health — La Jolla
Pennsylvania
- Fox Chase Cancer Center — Philadelphia
Texas
- University of Texas Southwestern — Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2030-09 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05197881
The ClinicalTrials.gov registry entry for NCT05197881 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Varian, a Siemens Healthineers Company, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cervical Cancer by FIGO Stage 2018 appearing as the primary indexed condition, and to 1 intervention — of which Varian Ethos Adaptive Radiation Therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05197881 reports 5 study locations spanning 5 distinct geographic areas — top geographies include Alabama, Arkansas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05197881 about?
NCT05197881 is a clinical study titled "Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix". This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modul...
What is the current status of trial NCT05197881?
This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2022-05-03. Estimated completion is 2030-09.
What conditions does trial NCT05197881 study?
This clinical trial studies the following conditions: Cervical Cancer by FIGO Stage 2018. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05197881?
The interventions under investigation include: Varian Ethos Adaptive Radiation Therapy (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05197881?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05197881 being conducted?
This trial has 5 study locations across Alabama, Arkansas, California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.